

Supplementary Table 1. Clinical and demographic characteristics of patients with peripheral SpA stratified for the presence of psoriasis.

Variable	DAPSA				PASDAS				ASDAS			
	pSpA without psoriasis (n = 49)		pSpA with psoriasis (n = 142)		pSpA without psoriasis (n = 42)		pSpA with psoriasis (n = 97)		pSpA without psoriasis (n = 82)		pSpA with psoriasis (n = 197)	
	Patients with an available assessment	Value	Patients with an available assessment	Value	Patients with an available assessment	Value	Patients with an available assessment	Value	Patients with an available assessment	Value	Patients with an available assessment	Value
Age, years	49	53.0 (12.5)	142	57.1 (11.1)	42	54.5 (10.9)	97	58.4 (9.9)	82	50.5 (13.4)	197	58.0 (11.4)
Female, n (%)	49	37 (75.5%)	142	66 (46.5%)	42	33 (78.6%)	97	43 (44.3%)	82	59 (72.0%)	197	111 (56.3%)
Symptom duration, years	39	11.6 (8.5)	101	14.1 (9.3)	36	11.6 (8.7)	76	14.0 (8.7)	64	10.7 (8.4)	149	13.5 (9.4)
Current NSAID use, n (%)	-	28 (57.1%)	-	63 (44.4%)	-	21 (50.0%)	-	49 (50.5%)	-	39 (47.6%)	-	93 (47.2%)
Current csDMARD use, n (%)	-	26 (53.1%)	-	91 (64.1%)	-	19 (45.2%)	-	51 (52.6%)	-	38 (46.3%)	-	120 (60.9%)
Current bDMARD use, n (%)	-	27 (55.1%)	-	70 (49.3%)	-	21 (50.0%)	-	55 (57.7%)	-	42 (51.2%)	-	95 (48.2%)
Current glucocorticoid use, n (%)	-	3 (6.4%)	-	7 (4.9%)	-	3 (7.1%)	-	7 (7.2%)	-	3 (3.7%)	-	11 (5.6%)
Disease activity												
DAPSA (0-∞)	49	10.6 (6.4)	142	9.7 (7.0)	39	9.7 (5.7)	90	9.4 (7.1)	45	9.8 (5.6)	114	9.6 (7.1)
PASDAS (0-10)	35	3.5 (1.4)	80	3.2 (1.4)	42	3.5 (1.5)	97	3.2 (1.3)	39	3.4 (1.5)	84	3.3 (1.3)
ASDAS (0-∞)	45	2.4 (1.0)	115	2.1 (1.0)	42	2.3 (1.0)	89	2.0 (1.0)	82	2.4 (1.0)	197	2.1 (1.0)
BASDAI (0-10)	46	4.7 (2.5)	116	4.0 (2.3)	41	4.6 (2.6)	91	3.9 (3.3)	82	4.5 (2.4)	197	3.9 (2.2)
PGA (0-10)	49	4.6 (2.7)	142	3.8 (2.6)	41	4.5 (2.7)	97	3.6 (2.6)	82	4.4 (2.7)	197	3.8 (2.5)
VAS pain (0-10)	49	4.2 (2.5)	142	3.7 (2.6)	42	4.1 (2.4)	90	3.5 (2.6)	59	4.4 (2.4)	171	3.7 (2.6)
PhGA (0-10)	39	1.9 (1.4)	105	1.7 (1.5)	42	2.1 (1.6)	97	1.9 (1.4)	57	1.9 (1.6)	127	1.8 (1.6)
CRP, mg/L (0-∞)	49	4.6 (5.3)	142	4.4 (6.2)	42	3.8 (4.3)	97	4.1 (5.9)	82	6.2 (14.1)	197	3.9 (5.9)
Psoriasis body surface area (0-100%)	NA	NA	106	1.9 (6.3)	NA	NA	90	2.0 (6.7)	NA	NA	123	1.8 (5.9)
Tender joint count (0-68)	49	1.0 (2.1)	142	1.2 (2.5)	42	0.5 (0.9)	97	1.4 (2.9)	43	0.6 (1.5)	138	1.2 (2.5)
Swollen joint count (0-66)	49	0.3 (0.7)	142	0.5 (1.0)	42	0.2 (0.6)	97	0.3 (1.0)	43	0.4 (1.2)	138	0.4 (1.0)
LEI score	47	0.2 (0.7)	114	0.0 (0.2)	42	0.1 (0.3)	97	0.0 (0.2)	64	0.1 (0.4)	137	0.0 (0.2)
Dactylitis (0-20)	47	0.0 (0.0)	114	0.1 (0.3)	42	0.0 (0.0)	97	0.0 (0.3)	64	0.0 (0.0)	137	0.1 (0.3)
Physical function and health impact												
HAQ-S (0-3)	36	0.9 (0.6)	92	0.8 (0.7)	33	0.9 (0.6)	73	0.7 (0.7)	48	0.9 (0.6)	146	0.7 (0.6)
ASAS-HI (0-17)	43	6.1 (3.9)	104	5.0 (3.4)	39	5.9 (4.0)	88	4.9 (3.4)	57	6.3 (3.9)	162	4.9 (3.3)
Health-related quality of life												
EQ-5D (0-1)	38	0.74 (0.21)	92	0.78 (0.18)	33	0.76 (0.22)	73	0.8 (0.2)	49	0.74 (0.23)	145	0.79 (0.17)
SF36 MCS (0-100)	43	48.2 (12.1)	112	50.0 (10.4)	42	48.4 (11.2)	97	49.7 (10.8)	57	47.2 (11.9)	171	50.3 (10.4)
SF36 PCS (0-100)	43	38.2 (9.3)	112	40.4 (10.8)	42	39.2 (10.3)	97	41.3 (10.8)	57	38.3 (9.9)	171	40.6 (10.1)

Values are presented as mean (SD) unless stated otherwise.

DAPSA = Disease Activity Psoriatic Arthritis Score, PASDAS = Psoriatic Arthritis Disease Activity Score, ASDAS = Ankylosing Spondylitis Disease Activity Score, NSAID = Non-Steroidal Anti Inflammatory Drug, cDMARD = conventional Disease Modifying Anti-Rheumatic Drug, bDMARD = biological Disease Modifying Anti-Rheumatic Drug, BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, PGA = Patient Global Assessment, VAS = Visual Analog Scale, PhGA = Physician Global Assessment, CRP = C-

Reactive Protein, LEI score = Leeds Enthesitis Index score, HAQ-S = Health Assessment Questionnaire for Spondyloarthritis, ASAS-HI = Assessment of SpondyloArthritis international Society Health Index, EQ-5D = EuroQol 5D, SF36 = Medical Outcomes Study 36-Question Short Form, MCS = Mental Component Score, PCS = Physical Component Score, SpA = Spondyloarthritis, NA = not applicable

Supplementary Table 2. Clinical and demographic characteristics of patients with axial SpA.

Variable	Axial SpA ASDAS (n= 249)	
	Patients with an available assessment	Value
Age, years	249	48.1 (13.3)
Female, n (%)	249	100 (40.2%)
Symptom duration, years	177	20.4 (13.5)
Current NSAID use, n (%)	-	159 (63.9%)
Current cDMARD use, n (%)	-	29 (11.6%)
Current bDMARD use, n (%)	-	137 (55.0%)
Current glucocorticoid use, n (%)	-	1 (0.4%)
Disease activity		
DAPSA (0-∞)	112	8.5 (5.2)
PASDAS (0-10)	94	3.3 (1.1)
ASDAS (0-∞)	249	2.3 (0.9)
BASDAI (0-10)	249	4.1 (2.2)
PGA (0-10)	249	4.2 (2.6)
VAS pain (0-10)	173	4.1 (2.5)
PhGA (0-10)	154	1.9 (1.5)
CRP, mg/L (0-∞)	249	4.8 (8.0)
Psoriasis body surface area (0-100%)	112	0.3 (1.1)
Tender joint count (0-68)	156	0.3 (0.8)
Swollen joint count (0-66)	156	0.1 (0.4)
LEI score (0-6)	188	0.2 (0.5)
Dactylitis count (0-20)	188	0.0 (0.1)
Physical function and health impact		
HAQ-S (0-3)	145	0.7 (0.5)
ASAS-HI (0-17)	151	5.5 (3.6)
Health-related quality of life		
EQ-5D (0-1)	142	0.78 (0.20)
SF36 MCS (0-100)	161	49.6 (11.9)
SF36 PCS (0-100)	161	41.1 (9.2)

Values are presented as mean (SD) unless stated otherwise.

DAPSA = Disease Activity Psoriatic Arthritis Score, PASDAS = Psoriatic Arthritis Disease Activity Score, ASDAS = Ankylosing Spondylitis Disease Activity Score, NSAID = Non-Steroidal Anti Inflammatory Drug, cDMARD = conventional Disease Modifying Anti-Rheumatic Drug, bDMARD = biological Disease Modifying Anti-Rheumatic Drug, BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, PGA = Patient Global Assessment, VAS = Visual Analog Scale, PhGA = Physician Global Assessment, CRP = C-Reactive Protein, LEI score = Leeds Enthesitis Index score, HAQ-S = Health Assessment Questionnaire for Spondyloarthritis, ASAS-HI = Assessment of SpondyloArthritis international Society Health Index, EQ-5D = EuroQol 5D, SF36 = Medical Outcomes Study 36-Question Short Form, MCS = Mental Component Score, PCS = Physical Component Score, SpA = Spondyloarthritis, NA = not applicable

Supplementary Table 3. A priori hypothesized correlations between DAPSA, PASDAS and ASDAS with outcome measures.

Outcome measure	DAPSA			PASDAS			ASDAS			
	Total pSpA population	Peripheral SpA		Total pSpA population	Peripheral SpA		Total pSpA population	Peripheral SpA		Axial SpA
Disease activity		PSpA without psoriasis	PSpA with psoriasis		PSpA without psoriasis	PSpA with psoriasis		pSpA without psoriasis	pSpA with psoriasis	Total axSpA population
DAPSA†				High	High	High	High	High	High	
PASDAS§	High	High	High				High	High	High	
ASDAS‡	High	High	High	High	High	High				
BASDAI‡	High	High	High	High	High	High				
PGA†, §, ‡										
VAS pain†				High	High	High	High	High	High	High
PhGA§	Moderate	Moderate	Moderate				Moderate - High	Moderate - High	Moderate - High	High
Psoriasis BSA			Low			Low			Low	Low
TJC68†, §							Very low - Low	Very low - Low	Very low - Low	Very low - Low
SJC66†, §							Very low - Low	Very low - Low	Very low - Low	Very low - Low
LEI score§	Very low - Low	Very low - Low	Very low - Low				Very low - Low	Very low - Low	Very low - Low	Very low - Low
Dactylitis count§	Very low	Very low	Very low				Very low	Very low	Very low	Very low
Physical function and health impact										
HAQ-S	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate
ASAS-HI	Low - Moderate	Low - Moderate	Low - Moderate	Low - Moderate	Low - Moderate	Low - Moderate	Low - Moderate	Low - Moderate	Low - Moderate	Low - Moderate
Health-related quality of life										
EQ-5D	Low - Moderate	Low - Moderate	Low - Moderate	Low - Moderate	Low - Moderate	Low - Moderate	Low - Moderate	Low - Moderate	Low - Moderate	Low - Moderate
SF36 MCS	Low	Low	Low	Low	Low	Low	Low	Low	Low	Low
SF36 PCS§	Moderate	Moderate	Moderate				Moderate	Moderate	Moderate	Moderate

† DAPSA components, § PASDAS components, ‡ ASDAS components, Individual components of the DAPSA, PASDAS and ASDAS were not included in the calculation of the frequency of confirmed hypotheses for concurrent validity
DAPSA = Disease Activity Psoriatic Arthritis Score, PASDAS = Psoriatic Arthritis Disease Activity Score, ASDAS = Ankylosing Spondylitis Disease Activity Score, BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, PGA = Patient Global Assessment, VAS= Visual Analog Scale, PhGA = Physician Global Assessment, CRP = C-Reactive Protein, LEI score = Leeds Enthesitis Index score, BSA = Body Surface Area, TJC68 = Tender Joint Count of 68 joints, SJC = Swollen Joint Count of 66 joints, HAQ-S = Health Assessment Questionnaire for Spondyloarthritis, ASAS-HI = Assessment of SpondyloArthritis international Society Health Index, EQ-5D = EuroQol 5D, SF36 = Medical Outcomes Study 36-Question Short Form, MCS = Mental Component Score, PCS = Physical Component Score, SpA = Spondyloarthritis, pSpA = peripheral Spondyloarthritis, axSpA = Axial Spondyloarthritis

Supplementary Table 4. Spearman correlations of the disease activity measures with outcomes measures in patients with simultaneously available DAPSA, PASDAS and ASDAS scores .

Outcome measure	DAPSA						PASDAS						ASDAS						
	Total pSpA population n=124		pSpA without psoriasis n=39		pSpA with psoriasis n=92		Total pSpA population n=124		pSpA without psoriasis n=39		pSpA with psoriasis n=92		Total pSpA population n=124		pSpA without psoriasis n=39		pSpA with psoriasis n=92		
	R _s	Hypothesis	R _s	Hypothesis	R _s	Hypothesis	R _s	Hypothesis	R _s	Hypothesis	R _s	Hypothesis	R _s	Hypothesis	R _s	Hypothesis	R _s	Hypothesis	
Disease activity																			
DAPSA	NA		NA		NA		0.90*	- H	0.85*	+	0.90*	- H	0.78*	+	0.77*	+	0.76*	+	
PASDAS§	0.90*	- H	0.85*	+	0.90*	- H	NA		NA		NA		0.85*	+	0.83*	+	0.84*	+	
ASDAS	0.78*	+	0.77*	+	0.76*	+	0.85*	+	0.83*	+	0.84*	+	NA		NA		NA		
BASDAI‡	0.77*	+	0.71*	+	0.77*	+	0.79*	+	0.67*	- L	0.80*	+	0.86*		0.82*		0.86*		
PGA‡, § †	0.89*		0.89*		0.87*		0.91*		0.87*		0.91*		0.83*		0.75*		0.82*		
VAS pain†	0.88*		0.94*		0.87*	+	0.73*	+	0.71*	+	0.72*	+	0.66*	- L	0.68*	+	0.62*	+	
PhGA§	0.65*	+	0.54*	+	0.68*		0.80*		0.72*		0.81*		0.53*	+	0.41*	- L	0.56*	- L	
CRP‡ † §	0.11		0.27		0.02		0.19*		0.36*		0.11		0.42*		0.55*		0.37*		
Psoriasis BSA	NA		NA		-0.00	- L	NA		NA		-0.01	- L	NA		NA		-0.01	- L	
TJC68† §	0.66*		0.67*		0.67*		0.55*		0.52*		0.59*		0.39*	+	0.33	+	0.44*	+	
SJC66† §	0.51*		0.36		0.52*		0.46*		0.28		0.53*		0.23*	+	0.09	+	0.32*	+	
LEI score §	0.02	+	0.08	+	-0.03	+	0.10		0.19		0.05		-0.00	+	0.04	+	-0.08	+	
Dactylitis count§	0.19*	+	ND		0.22*	+	0.20		ND		0.25*		0.17	+	ND		0.21	+	
Physical function and health impact																			
HAQ-S	0.63*	+	0.80*	+	0.57*	+	0.68*	+	0.71*	- H	0.67*	+	0.70*	- H	0.75*	- H	0.68*	+	
ASAS-HI	0.69*	+	0.69*	+	0.67*	+	0.70*	- H	0.61*	+	0.69*	+	0.71*	- H	0.73*	- H	0.69*	+	
Health-related quality of life																			
EQ-5D	-0.50*	+	-0.51*	+	-0.48*	+	-0.50*	+	-0.40*	+	-0.54*	+	-0.57*	+	-0.59*	+	-0.55*	+	
SF36 MCS	-0.23*	- L	-0.32*	+	-0.19*	- L	-0.18*	- L	-0.32*	+	-0.15	- L	-0.28*	- L	-0.50*	+	-0.19*	- L	
SF36 PCS§	-0.69*	+	-0.75*	+	-0.66*	+	-0.78*		-0.80*		-0.76*		-0.73*	- H	-0.80*	- H	-0.70*	- H	

† DAPSA components, § PASDAS components, ‡ ASDAS components Individual components of the DAPSA, PASDAS and ASDAS were not included in the calculation of the frequency of confirmed hypotheses for concurrent validity

ND = Correlation could not be calculated as the standard deviation was zero, *Correlation is statistically significant at the 0.05 level (two-tailed), + = strength of correlation as hypothesized, L = strength of correlation is lower than hypothesized, H = strength of correlation is higher than hypothesized,

DAPSA = Disease Activity Psoriatic Arthritis Score, PASDAS = Psoriatic Arthritis Disease Activity Score, ASDAS = Ankylosing Spondylitis Disease Activity Score, BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, PGA = Patient Global Assessment, VAS= Visual Analog Scale, PhGA = Physician Global Assessment, CRP = C-Reactive Protein, LEI score = Leeds Enthesitis Index score, BSA = Body Surface Area, TJC68 = Tender Joint Count of 68 joints, SJC = Swollen Joint Count of 66 joints, HAQ-S = Health Assessment Questionnaire for Spondyloarthritis, ASAS-HI = Assessment of SpondyloArthritis international Society Health Index, EQ-5D = EuroQol 5D, SF36 = Medical Outcomes Study 36-Question Short Form, MCS = Mental Component Score, PCS = Physical Component Score, SpA = Spondyloarthritis, pSpA = peripheral Spondyloarthritis, axSpA = Axial Spondyloarthritis,

Supplementary Table 5. Outcome measures stratified for disease activity states in patients with simultaneously available DAPSA, PASDAS and ASDAS scores.

Outcome measure	DAPSA Total pSpA population n = 124				PASDAS Total pSpA population n = 124						ASDAS Total pSpA population n = 124							
	DAPSA cut-offs				One-way ANOVA		PASDAS cut-offs				One-way ANOVA		ASDAS cut-offs				One-way ANOVA	
	≤4 n = 33 (26.6%)	5 to ≤14 n = 64 (51.6%)	15 to ≤28 n = 26 (21.0%)	≥29 n = 1 (0.8%)	F-value	P-value	≤1.9 n = 18 (14.5%)	1.9 to <3.2 n = 36 (29.0%)	3.2 to <5.4 n = 65 (52.4%)	≥5.4 n = 5 (4.0%)	F-value	P-value	<1.3 n = 30 (24.2%)	1.3 to <2.1 n = 34 (27.4%)	2.1 to ≤3.5 n = 46 (37.1%)	>3.5 n = 14 (11.3%)	F-value	P-value
DAPSA (0-∞)	2.2 (1.4)	9.4 (2.9)	19.1 (3.7)	29.2 (-)	197.1	<0.01	1.7 (2.0)	5.4 (2.7)	13.3 (5.2)	22.1 (3.6)	66.0	<0.01	3.2 (3.0)	7.2 (4.8)	13.5 (5.6)	16.9 (4.2)	43.1	<0.01
PASDAS (0-10)	1.8 (0.9)	3.5 (0.8)	5.0 (0.6)	3.3 (-)	86.6	<0.01	1.0 (0.5)	2.7 (0.4)	4.2 (0.6)	5.9 (0.4)	259.6	<0.01	1.8 (0.9)	3.0 (1.0)	4.2 (0.7)	4.8 (0.6)	65.9	<0.01
ASDAS (0-∞)	1.1 (0.5)	2.2 (0.7)	3.1 (0.8)	2.2 (-)	43.1	<0.01	0.9 (0.4)	1.5 (0.6)	2.7 (0.7)	3.2 (0.9)	61.3	<0.01	0.9 (0.3)	1.7 (0.2)	2.7 (0.3)	3.8 (0.3)	423.7	<0.01
BASDAI (0-10)	1.6 (1.5)	4.5 (1.8)	6.2 (1.9)	6.0 (-)	36.9	<0.01	1.0 (0.8)	2.8 (1.6)	5.5 (1.7)	7.0 (1.8)	53.1	<0.01	1.4 (1.0)	3.2 (1.4)	5.8 (1.3)	6.8 (1.6)	93.1	<0.01
PGA (0-10)	1.1 (1.0)	4.1 (1.8)	7.3 (1.6)	4.0 (-)	74.5	<0.01	0.4 (0.7)	2.1 (1.0)	5.6 (1.7)	8.6 (1.1)	101.1	<0.01	1.1 (1.1)	2.9 (1.9)	5.6 (1.7)	7.1 (1.5)	71.8	<0.01
VAS pain (0-10)	0.7 (0.7)	4.2 (1.8)	6.5 (1.5)	5.0 (-)	75.2	<0.01	0.9 (2.0)	2.6 (2.2)	4.9 (1.8)	7.4 (0.8)	30.8	<0.01	1.7 (2.3)	2.9 (2.2)	5.0 (1.8)	6.1 (1.4)	25.1	<0.01
PhGA (0-10)	1.0 (0.9)	1.8 (1.0)	3.5 (1.3)	1.0 (-)	29.9	<0.01	0.3 (0.4)	1.5 (0.9)	2.4 (1.0)	5.2 (1.8)	49.1	<0.01	1.0 (1.1)	1.6 (1.0)	2.4 (1.2)	3.0 (1.8)	12.5	<0.05
CRP, mg/L (0-∞)	2.5 (2.3)	3.4 (3.6)	7.5 (9.7)	2.0 (-)	5.0	<0.01	2.9 (2.9)	2.0 (1.5)	5.2 (7.0)	5.4 (6.2)	3.1	<0.05	1.8 (1.2)	2.5 (2.5)	4.0 (5.2)	11.8 (9.8)	15.6	<0.01
TJC68 (0-68)	0.1 (0.3)	0.6 (1.0)	3.2 (3.1)	20.0 (-)	68.8	<0.01	0.0 (0.0)	0.3 (0.6)	1.8 (3.3)	3.6 (1.1)	6.0	<0.01	0.2 (0.6)	0.7 (1.2)	2.0 (3.8)	1.7 (2.0)	3.8	<0.05
SJC66 (0-66)	0.1 (0.3)	0.1 (0.3)	1.4 (1.6)	0.0 (-)	19.0	<0.01	0.0 (0.0)	0.2 (0.4)	0.5 (1.0)	2.0 (2.0)	7.9	<0.01	0.1 (0.4)	0.4 (0.8)	0.4 (1.1)	0.7 (1.4)	1.6	0.20
LEI score (0-6)	0.0 (0.2)	0.1 (0.2)	0.0 (0.2)	0.0 (-)	0.2	0.90	0.0 (0.0)	0.1 (0.2)	0.1 (0.2)	0.2 (0.4)	1.1	0.33	0.0 (0.2)	0.1 (0.2)	0.1 (0.3)	0.0 (0.0)	0.4	0.75
Dactylitis (0-20)	0.0 (0.0)	0.0 (0.0)	0.2 (0.6)	0.0 (-)	2.1	0.11	0.0 (0.0)	0.0 (0.0)	0.1 (0.4)	0.2 (0.4)	0.9	0.46	0.0 (0.0)	0.0 (0.0)	0.1 (0.4)	0.1 (0.3)	0.6	0.64
Physical function and health impact																		
HAQ-S (0-3)	0.2 (0.2)	1.0 (0.5)	1.3 (0.8)	0.9 (-)	20.0	<0.01	0.1 (0.15)	0.5 (0.4)	1.2 (0.6)	1.9 (0.6)	27.0	<0.01	0.2 (0.3)	0.7 (0.6)	1.2 (0.5)	1.4 (0.7)	22.4	<0.01
ASAS-HI (0-17)	1.7 (1.7)	6.0 (3.1)	7.7 (3.5)	10.0 (-)	25.0	<0.01	1.5 (1.9)	3.2 (2.0)	7.2 (3.3)	8.2 (3.2)	30.4	<0.01	2.0 (1.7)	3.9 (2.6)	7.3 (3.0)	8.7 (3.5)	32.8	<0.01
Health-related quality of life																		
EQ-5D (0-1)	0.91 (0.11)	0.76 (0.14)	0.63 (0.31)	0.81 (-)	9.3	<0.01	0.92 (0.13)	0.85 (0.11)	0.69 (0.2)	0.87 (0.11)	8.2	<0.01	0.91 (0.09)	0.82 (0.16)	0.71 (0.21)	0.60 (0.29)	10.2	<0.01
SF36 MCS (0-100)	54.9 (7.2)	46.2 (11.1)	48.6 (12.0)	48.6 (-)	4.3	<0.01	56.3 (6.2)	49.8 (9.7)	47.0 (11.6)	53.1 (12.2)	3.9	<0.05	53.1 (8.1)	52.2 (11.4)	45.6 (10.6)	47.5 (11.8)	4.3	<0.01
SF36 PCS (0-100)	51.0 (5.6)	38.4 (8.5)	31.9 (9.1)	43.1 (-)	30.6	<0.01	52.5 (4.8)	46.2 (7.6)	35.2 (7.4)	22.9 (9.5)	45.6	<0.01	50.8 (6.1)	42.8 (9.6)	34.7 (7.9)	31.2 (5.4)	33.8	<0.01

Values are presented as mean (SD) unless stated otherwise. Included number of patients might be lower due to missing outcome measures. Correlation is statistically significant at the 0.05 level (two-tailed)

DAPSA = Disease Activity Psoriatic Arthritis Score, PASDAS = Psoriatic Arthritis Disease Activity Score, ASDAS = Ankylosing Spondylitis Disease Activity Score, BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, PGA = Patient Global Assessment, VAS = Visual Analog Scale, PhGA = Physician Global Assessment, CRP = C-Reactive Protein, BSA = Body Surface Area, LEI score = Leeds Enthesitis Index score, TJC68 = Tender Joint Count of 68 joints, SJC66 = Swollen Joint Count of 66 joints, HAQ-S = Health Assessment Questionnaire for Spondyloarthritis, ASAS-HI = Assessment of SpondyloArthritis international Society Health Index, EQ-5D = EuroQol 5D, SF36 = Medical Outcomes Study 36-Question Short Form, MCS = Mental Component Score, PCS = Physical Component Score, pSpA = peripheral Spondyloarthritis

Supplementary Table 6. Outcome measures stratified for DAPSA disease activity states for peripheral SpA with and without psoriasis.

Outcome measure	DAPSA Peripheral SpA with psoriasis n = 142						DAPSA Peripheral SpA without psoriasis n = 49					
	DAPSA cut-offs				One-way ANOVA		DAPSA cut-offs				One-way ANOVA	
	≤4 n = 38 (26.8%)	5 to ≤14 n = 74 (52.1%)	15 to ≤28 n = 28 (19.7%)	≥29 n = 2 (1.4%)	F-value	P-value	≤4 n = 11 (22.4%)	5 to ≤14 n = 25 (51.0%)	15 to ≤28 n = 13 (26.5%)	≥29 n = 0 (0.0%)	F-value	P-value
DAPSA (0-∞)	2.1 (1.3)	9.2 (3.0)	19.0 (2.9)	34.7 (7.8)	266.1	<0.01	2.0 (1.5)	10.2 (2.6)	18.6 (3.4)	- (-)	116.8	<0.01
PASDAS (0-10)	1.8 (0.7)	3.2 (0.8)	4.9 (0.6)	- (-)	88.0	<0.01	1.6 (1.2)	3.8 (0.4)	5.1 (0.7)		51.0	<0.01
ASDAS (0-∞)	1.1 (0.4)	2.1 (0.7)	3.3 (0.9)	3.2 (-)	46.7	<0.01	1.0 (0.6)	2.5 (0.7)	3.2 (0.8)	- (-)	29.7	<0.01
BASDAI (0-10)	1.8 (1.5)	4.3 (1.8)	6.2 (1.9)	7.6 (-)	32.8	<0.01	1.5 (1.8)	5.3 (1.8)	6.3 (1.9)	- (-)	20.4	<0.01
PGA (0-10)	1.1 (0.9)	3.8 (1.9)	7.1 (1.6)	7.5 (0.7)	76.1	<0.01	0.8 (1.0)	4.7 (1.4)	7.5 (1.6)	- (-)	72.3	<0.01
VAS pain (0-10)	0.7 (0.7)	4.0 (1.9)	6.9 (1.4)	6.3 (1.0)	89.5	<0.01	0.8 (0.6)	4.6 (1.7)	6.4 (1.4)	- (-)	44.9	<0.01
PhGA (0-10)	0.8 (0.9)	1.5 (1.0)	3.0 (1.6)	8.0 (-)	25.4	<0.01	0.8 (1.0)	1.7 (1.1)	3.7 (1.3)	- (-)	15.0	<0.01
CRP, mg/L (0-∞)	2.3 (1.8)	3.8 (4.1)	8.0 (10.7)	13.5 (16.3)	6.9	<0.01	2.3 (3.0)	4.6 (4.3)	6.6 (7.7)	- (-)	2.1	0.14
Psoriasis BSA (0-100%)	1.1 (1.9)	2.6 (8.6)	1.4 (3.2)	- (-)	0.63	0.54	NA	NA	NA	NA	NA	NA
TJC68 (0-68)	0.1 (0.3)	0.7 (1.2)	3.1 (2.1)	15.5 (9.2)	86.7	<0.01	0.0 (0.0)	0.3 (0.6)	3.2 (3.1)	- (-)	15.0	<0.01
SJC66 (0-66)	0.0 (0.0)	0.3 (0.7)	1.2 (1.4)	4.0 (1.4)	24.2	<0.01	0.2 (0.6)	0.1 (0.3)	0.9 (1.1)	- (-)	5.7	<0.01
LEI score (0-6)	0.0 (0.0)	0.1 (0.3)	0.1 (0.2)	0.0 (-)	0.8	0.48	0.0 (0.0)	0.2 (0.5)	0.4 (1.2)	- (-)	1.1	0.34
Dactylitis count (0-20)	0.0 (0.0)	0.0 (0.1)	0.2 (0.7)	0.0 (-)	2.8	<0.05	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	- (-)	-	=
Physical function and health impact												
HAQ-S (0-3)	0.2 (0.3)	0.9 (0.6)	1.2 (0.8)	1.0 (-)	11.4	<0.01	0.1 (0.2)	1.1 (0.4)	1.1 (0.6)	- (-)	16.5	<0.01
ASAS-HI (0-17)	1.9 (1.7)	5.3 (2.9)	7.6 (3.1)	11.0 (-)	22.0	<0.01	1.5 (1.6)	7.5 (3.0)	7.3 (3.8)	- (-)	15.1	<0.01
Health-related quality of life												
EQ-5D (0-1)	0.94 (0.07)	0.78 (0.10)	0.64 (0.22)	0.41 (-)	22.3	<0.01	0.94 (0.05)	0.71 (0.14)	0.63 (0.28)	- (-)	7.6	<0.01
SF36 MCS (0-100)	55.2 (7.7)	48.4 (10.2)	48.5 (10.7)	22.1 (-)	6.3	<0.01	56.2 (4.9)	45.4 (12.6)	46.3 (13.3)	- (-)	3.2	0.05
SF36 PCS (0-100)	49.7 (7.3)	39.2 (9.7)	32.3 (8.6)	35.9 (-)	18.7	<0.01	49.8 (5.8)	36.6 (6.0)	31.5 (7.7)	- (-)	23.2	<0.01

Values are expressed as mean (SD) unless stated otherwise. Included number of patients might be lower due to missing outcome measures. Correlation is statistically significant at the 0.05 level (two-tailed)

DAPSA = Disease Activity Psoriatic Arthritis Score, PASDAS = Psoriatic Arthritis Disease Activity Score, ASDAS = Ankylosing Spondylitis Disease Activity Score, BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, PGA = Patient Global Assessment, VAS= Visual Analog Scale, PhGA = Physician Global Assessment, CRP = C-Reactive Protein, BSA = Body Surface Area, TJC68 = Tender Joint Count of 68 joints, SJC66 = Swollen Joint Count of 66 joints, HAQ-S = Health Assessment

Questionnaire for Spondyloarthritis, ASAS-HI = Assessment of SpondyloArthritis international Society Health Index, EQ-5D = EuroQol 5D, SF36 = Medical Outcomes Study 36-Question Short Form, MCS = Mental Component Score, PCS = Physical Component Score, SpA = spondyloarthritis, NA = Not Applicable

Supplementary Table 7. Outcome measures stratified for ASDAS disease activity states for peripheral SpA with and without psoriasis.

Outcome measure	PASDAS Peripheral SpA with psoriasis n = 97						PASDAS Peripheral SpA without psoriasis n = 42					
	PASDAS cut-offs				One-way ANOVA		PASDAS cut-offs				One-way ANOVA	
	≤1.9 n = 17 (17.5%)	1.9 to <3.2 n = 34 (35.1%)	3.2 to <5.4 n = 42 (43.3%)	≥5.4 n = 4 (4.1%)	F-value	P-value	≤1.9 n = 6 (14.3%)	1.9 to <3.2 n = 6 (14.3%)	3.2 to <5.4 n = 27 (64.3%)	≥5.4 n = 3 (7.1%)	F-value	P-value
DAPSA (0-∞)	1.9 (2.1)	5.7 (2.9)	14.4 (5.9)	22.5 (3.7)	47.8	<0.01	1.0 (0.9)	4.9 (3.0)	11.6 (3.2)	21.6 (5.0)	31.4	<0.01
PASDAS (0-10)	1.2 (0.5)	2.7 (0.4)	4.2 (0.6)	5.8 (0.4)	211.1	<0.01	0.6 (0.4)	2.7 (0.5)	4.0 (0.5)	5.9 (0.3)	111.3	<0.01
ASDAS (0-∞)	0.9 (0.3)	1.5 (0.6)	2.7 (0.7)	3.5 (1.1)	41.1	<0.01	0.8 (0.4)	1.4 (0.6)	2.7 (0.7)	3.2 (0.0)	20.6	<0.01
BASDAI (0-10)	1.2 (0.9)	2.8 (1.6)	5.2 (1.7)	7.1 (1.6)	33.2	<0.01	0.5 (0.2)	3.0 (0.2)	5.7 (1.7)	6.8 (2.4)	18.7	<0.01
PGA (0-10)	0.5 (0.7)	2.2 (1.1)	5.5 (1.9)	8.5 (0.6)	74.6	<0.01	0.2 (0.4)	1.8 (1.0)	5.6 (1.6)	8.0 (1.7)	35.9	<0.01
VAS pain (0-10)	1.0 (2.1)	2.7 (2.2)	4.8 (1.9)	7.6 (0.3)	18.5	<0.01	0.5 (0.4)	2.2 (1.9)	5.1 (1.7)	7.1 (1.5)	16.3	<0.01
PhGA (0-10)	0.4 (0.6)	1.4 (0.9)	2.5 (0.9)	5.6 (2.1)	44.8	<0.01	0.1 (0.2)	1.6 (0.7)	2.3 (1.1)	5.6 (1.1)	23.3	<0.01
CRP, mg/L (0-∞)	3.1 (2.7)	2.6 (3.2)	5.6 (7.9)	6.8 (6.8)	2.0	0.12	3.3 (3.9)	1.3 (0.8)	4.4 (4.8)	4.0 (5.2)	0.8	0.50
Psoriasis BSA (0-100%)	1.9 (3.8)	3.1 (10.7)	1.1 (1.8)	1.7 (2.1)	0.5	0.68	-	-	-	-	-	-
TJC68 (0-68)	0.1 (0.2)	0.4 (0.6)	2.6 (3.9)	3.8 (1.3)	7.1	<0.01	0.0 (0.0)	0.2 (0.4)	0.4 (0.7)	2.3 (2.1)	7.0	<0.01
SJC66 (0-66)	0.1 (0.2)	0.1 (0.3)	0.7 (1.2)	2.3 (2.2)	8.4	<0.01	0.0 (0.0)	0.5 (0.8)	0.1 (0.3)	1.3 (1.5)	6.4	<0.01
LEI score (0-6)	0.0 (0.0)	0.1 (0.2)	0.0 (0.2)	0.0 (0.0)	5.3	0.66	0.0 (0.0)	0.0 (0.0)	0.1 (0.3)	0.3 (0.6)	1.3	0.28
Dactylitis count (0-20)	0.0 (0.0)	0.0 (0.0)	0.1 (0.5)	0.3 (0.5)	1.0	0.41	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	-	-
Physical function and health impact												
HAQ-S (0-3)	0.1 (2.0)	0.5 (0.4)	1.2 (0.7)	2.3 (-)	16.3	<0.01	0.1 (0.2)	0.4 (0.4)	1.1 (0.5)	1.8 (0.3)	11.9	<0.01
ASAS-HI (0-17)	1.9 (2.0)	3.3 (2.3)	6.9 (3.0)	8.0 (4.6)	17.8	<0.01	0.4 (0.5)	3.3 (1.8)	7.4 (3.6)	8.5 (0.7)	8.7	<0.01
Health-related quality of life												
EQ-5D (0-1)	0.95 (0.07)	0.84 (0.11)	0.69 (0.22)	0.91 (0.13)	7.8	<0.01	0.84 (0.22)	0.90 (0.08)	0.71 (0.24)	0.81 (-)	1.2	0.32
SF36 MCS (0-100)	53.5 (11.6)	48.6 (9.6)	49.5 (11.0)	44.7 (16.2)	1.1	0.35	56.5 (4.0)	54.1 (5.4)	44.2 (11.6)	58.9 (1.2)	4.8	<0.01
SF36 PCS (0-100)	49.8 (8.1)	47.3 (7.8)	34.3 (7.7)	27.6 (11.7)	27.8	<0.01	55.4 (2.4)	44.1 (6.6)	36.6 (6.7)	20.4 (2.3)	26.6	<0.01

Values are expressed as mean (SD) unless stated otherwise. Included number of patients might be lower due to missing outcome measures. Correlation is statistically significant at the 0.05 level (two-tailed)

ASDAS = Ankylosing Spondylitis Disease Activity Score, PASDAS = Psoriatic Arthritis Disease Activity Score, DAPSA = Disease Activity Psoriatic Arthritis Score, BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, PGA = Patient Global Assessment, VAS = Visual Analog Scale, PhGA = Physician Global Assessment, CRP = C-Reactive Protein, BSA = Body Surface Area, TJC68 = Tender Joint Count of 68 joints, SJC66 = Swollen Joint Count of 66 joints, LEI score = Leeds Enthesitis Index

score, HAQ-S = Health Assessment Questionnaire for Spondyloarthritis, ASAS-HI = Assessment of SpondyloArthritis international Society Health Index, EQ-5D = EuroQol 5D, SF36 = Medical Outcomes Study 36-Question Short Form, MCS = Mental Component Score, PCS = Physical Component Score, SpA = Spondyloarthritis, NA = Not Applicable

Supplementary Table 8. Outcome measures stratified for ASDAS disease activity states for peripheral SpA with and without psoriasis.

Outcome measure	ASDAS Peripheral SpA with psoriasis n = 197						ASDAS Peripheral SpA without psoriasis n = 82					
	ASDAS cut-offs				One-way ANOVA		ASDAS cut-offs				One-way ANOVA	
	<1.3 n = 44 (22.3%)	1.3 to <2.1 n = 66 (33.5%)	2.1 to ≤3.5 n = 67 (34.0%)	>3.5 n = 20 (10.2%)	F-value	P-value	<1.3 n = 15 (18.3%)	1.3 to <2.1 n = 17 (20.7%)	2.1 to ≤3.5 n = 38 (46.3%)	>3.5 n = 12 (14.6%)	F-value	P-value
DAPSA (0-∞)	3.4 (3.0)	7.1 (4.8)	13.0 (6.8)	18.3 (3.3)	35.8	<0.01	2.8 (2.9)	7.5 (5.1)	12.6 (3.9)	14.1 (3.4)	16.3	<0.01
PASDAS (0-10)	1.9 (0.9)	3.1 (1.0)	4.1 (0.7)	5.0 (0.7)	42.2	<0.01	1.3 (1.0)	3.1 (1.1)	4.2 (0.8)	4.5 (0.4)	23.5	<0.01
ASDAS (0-∞)	0.9 (0.3)	1.7 (0.2)	2.6 (0.4)	3.9 (0.4)	506.7	<0.01	0.8 (0.3)	1.8 (0.3)	2.8 (0.4)	3.9 (0.5)	201.9	<0.01
BASDAI (0-10)	1.5 (0.9)	3.2 (1.4)	5.2 (1.5)	7.0 (1.4)	107.4	<0.01	1.4 (0.8)	3.3 (1.5)	5.6 (1.7)	6.8 (1.4)	40.8	<0.01
PGA (0-10)	1.3 (1.2)	3.1 (1.7)	5.1 (2.1)	7.6 (1.3)	80.2	<0.01	0.7 (0.7)	3.6 (2.0)	5.4 (1.9)	7.1 (1.6)	37.8	<0.01
VAS pain (0-10)	1.6 (2.1)	2.9 (2.0)	5.1 (2.1)	6.7 (1.0)	41.2	<0.01	1.6 (2.4)	3.0 (2.0)	5.6 (1.6)	5.5 (1.6)	14.7	<0.01
PhGA (0-10)	1.0 (1.1)	1.6 (1.2)	2.2 (1.7)	3.8 (2.0)	12.0	<0.01	0.8 (1.0)	1.5 (1.1)	2.5 (1.7)	2.2 (0.9)	4.2	0.11
CRP, mg/L (0-∞)	1.7 (1.1)	2.4 (2.5)	4.3 (4.8)	12.8 (12.3)	25.8	<0.01	1.5 (1.2)	2.7 (2.7)	5.5 (6.8)	19.2 (32.6)	5.0	<0.01
Psoriasis BSA (0-100%)	3.2 (10.7)	1.1 (2.3)	1.1 (1.3)	2.0 (3.9)	1.0	0.39	NA	NA	NA	NA	NA	NA
TJC68 (0-68)	0.3 (0.6)	0.8 (1.3)	1.9 (3.6)	2.5 (2.1)	5.0	<0.01	0.1 (0.3)	0.6 (1.2)	0.9 (1.9)	0.6 (0.8)	1.0	0.40
SJC66 (0-66)	0.0 (0.2)	0.4 (0.8)	0.6 (1.2)	0.9 (1.4)	3.4	<0.05	0.2 (0.6)	0.5 (1.0)	0.5 (1.6)	0.0 (0.0)	0.4	0.73
LEI score (0-6)	0.0 (0.0)	0.0 (0.2)	0.1 (0.3)	0.0 (0.0)	1.6	0.18	0.0 (0.0)	0.2 (0.4)	0.2 (0.5)	0.3 (0.5)	0.6	0.61
Dactylitis count (0-20)	0.1 (0.3)	0.0 (0.1)	0.1 (0.3)	0.1 (0.4)	0.6	0.62	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	-	-
Physical function and health impact												
HAQ-S (0-3)	0.3 (0.3)	0.6 (0.6)	1.0 (0.6)	1.4 (0.7)	19.7	<0.01	0.2 (0.2)	0.6 (0.6)	1.1 (0.5)	1.2 (0.4)	10.3	<0.05
ASAS-HI (0-17)	2.4 (1.7)	4.3 (2.7)	6.3 (3.4)	8.1 (3.1)	22.2	<0.01	1.6 (1.3)	4.0 (2.7)	8.1 (2.9)	8.6 (3.6)	15.3	<0.01
Health-related quality of life												
EQ-5D (0-1)	0.92 (0.09)	0.81 (0.14)	0.73 (0.14)	0.63 (0.21)	18.6	<0.01	0.95 (0.05)	0.83 (0.10)	0.66 (0.23)	0.64 (0.30)	4.8	<0.05
SF36 MCS (0-100)	54.0 (8.2)	51.0 (10.1)	48.3 (10.4)	46.1 (12.7)	3.5	<0.05	56.5 (3.3)	56.1 (7.9)	41.2 (11.0)	42.6 (12.2)	10.3	<0.01
SF36 PCS (0-100)	48.9 (7.0)	43.3 (8.9)	35.4 (8.8)	30.8 (5.4)	32.1	<0.01	50.0 (7.5)	41.0 (9.1)	35.2 (6.4)	31.0 (4.3)	15.4	<0.01

Values are expressed as mean (SD) unless stated otherwise. Included number of patients might be lower due to missing outcome measures. Correlation is statistically significant at the 0.05 level (two-tailed)

ASDAS = Ankylosing Spondylitis Disease Activity Score, PASDAS = Psoriatic Arthritis Disease Activity Score, DAPSA = Disease Activity Psoriatic Arthritis Score, BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, PGA = Patient Global Assessment, VAS = Visual Analog Scale, PhGA = Physician Global Assessment, CRP = C-Reactive Protein, BSA = Body Surface Area, TJC68 = Tender Joint Count of 68 joints, SJC66 = Swollen Joint Count of 66 joints, LEI score = Leeds Enthesitis Index

score, HAQ-S = Health Assessment Questionnaire for Spondyloarthritis, ASAS-HI = Assessment of SpondyloArthritis international Society Health Index, EQ-5D = EuroQol 5D, SF36 = Medical Outcomes Study 36-Question Short Form, MCS = Mental Component Score, PCS = Physical Component Score, SpA = Spondyloarthritis, NA = Not Applicable

Supplementary Table 9. Spearman correlations of ASDAS with outcomes measures in axial SpA.

Outcome measure	Total axSpA Population with ≥ 1 ASDAS n = 249	
	R_s	Hypothesis
Disease activity		
BASDAI‡	0.85*	
PGA‡	0.85*	
VAS pain	0.74*	+
PhGA	0.36*	- L
CRP ‡	0.47*	
Psoriasis BSA	0.12	- L
TJC68	0.15	+
SJC66	0.15	+
LEI score	0.05	+
Dactylitis count	-0.02	+
Physical function and health impact		
HAQ-S	0.53	+
ASAS-HI	0.56	+
Health-related quality of life		
EQ-5D	-0.41	+
SF36 MCS	-0.30	+
SF36 PCS	-0.60	+

‡ ASDAS components, Individual components of the ASDAS were not included in the calculation of the frequency of confirmed hypotheses for concurrent validity, *Correlation is statistically significant at the 0.05 level (two-tailed), + = strength of correlation as hypothesized, L = strength of correlation is lower than hypothesized, H = strength of correlation is higher than hypothesized

ASDAS = Ankylosing Spondylitis Disease Activity Score, BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, PGA = Patient Global Assessment, VAS= Visual Analog Scale, PhGA = Physician Global Assessment, CRP = C-Reactive Protein, LEI score = Leeds Enthesitis Index score, BSA = Body Surface Area, TJC68 = Tender Joint Count of 68 joints, SJC = Swollen Joint Count of 66 joints, HAQ-S = Health Assessment Questionnaire for Spondyloarthritis, ASAS-HI = Assessment of SpondyloArthritis international Society Health Index, EQ-5D = EuroQol 5D, SF36 = Medical Outcomes Study 36-Question Short Form, MCS = Mental Component Score, PCS = Physical Component Score, SpA = Spondyloarthritis, pSpA = peripheral Spondyloarthritis, axSpA = Axial Spondyloarthritis

Supplementary Table 10. Outcome measures stratified for ASDAS disease activity states in axial SpA.

Outcome measure	ASDAS				One-way ANOVA	
	Total axSpA population n = 249				F-value	P-value
	ASDAS cut-offs					
<1.3 n = 49 (19.7%)	1.3 to <2.1 n = 64 (25.7%)	2.1 to ≤3.5 n = 114 (45.8%)	>3.5 n = 22 (8.8%)			
ASDAS (0-∞)	1.0 (0.3)	1.7 (0.2)	2.8 (0.4)	4.0 (0.5)	580.9	<0.01
BASDAI (0-10)	1.6 (0.9)	3.0 (1.2)	5.3 (1.5)	7.4 (1.2)	154.1	<0.01
PGA (0-10)	1.3 (1.0)	2.9 (1.6)	5.7 (2.0)	7.5 (1.4)	118.9	<0.01
VAS pain (0-10)	1.6 (1.9)	3.0 (1.9)	5.2 (1.9)	7.4 (0.7)	51.8	<0.01
PhGA (0-10)	1.2 (1.0)	1.5 (1.0)	2.3 (1.7)	2.2 (1.6)	6.3	<0.01
CRP, mg/L (0-∞)	1.7 (1.4)	2.9 (2.9)	4.9 (6.7)	16.5 (17.6)	24.7	<0.01
TJC68 (0-68)	0.1 (0.4)	0.3 (0.7)	0.5 (1.0)	0.0 (0.0)	2.4	0.07
SJC66 (0-66)	0.0 (0.0)	0.1 (0.3)	0.2 (0.6)	0.0 (0.0)	1.4	0.25
LEI score (0-6)	0.2 (0.6)	0.0 (0.1)	0.2 (0.6)	0.3 (0.7)	1.3	0.29
Dactylitis count (0-20)	0.0 (0.0)	0.0 (0.1)	0.0 (0.1)	0.0 (0.0)	0.4	0.79
Physical function and health impact						
HAQ-S (0-3)	0.3 (0.2)	0.7 (0.5)	0.8 (0.5)	1.1 (0.5)	15.1	<0.01
ASAS-HI (0-17)	2.2 (2.3)	5.2 (3.2)	6.7 (3.1)	9.0 (3.9)	22.0	<0.01
Health-related quality of life						
EQ-5D (0-1)	0.89 (0.14)	0.83 (0.14)	0.74 (0.20)	0.62 (0.28)	8.4	<0.01
SF36 MCS (0-100)	55.0 (6.9)	52.7 (10.0)	47.4 (12.1)	37.8 (16.5)	9.3	<0.01
SF36 PCS (0-100)	48.6 (7.2)	43.6 (8.7)	37.7 (7.4)	32.7 (8.6)	21.5	<0.01

Values are presented as mean (SD) unless stated otherwise.

DAPSA = Disease Activity Psoriatic Arthritis Score, PASDAS = Psoriatic Arthritis Disease Activity Score, ASDAS = Ankylosing Spondylitis Disease Activity Score, NSAID = Non-Steroidal Anti Inflammatory Drug, cDMARD = conventional Disease Modifying Anti-Rheumatic Drug, bDMARD = biological Disease Modifying Anti-Rheumatic Drug, BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, PGA = Patient Global Assessment, VAS = Visual Analog Scale, PhGA = Physician Global Assessment, CRP = C-Reactive Protein, LEI score = Leeds Enthesitis Index score, HAQ-S = Health Assessment Questionnaire for Spondyloarthritis, ASAS-HI = Assessment of SpondyloArthritis international Society Health Index, EQ-5D = EuroQoL 5D, SF36 = Medical Outcomes Study 36-Question Short Form, MCS = Mental Component Score, PCS = Physical Component Score, SpA = Spondyloarthritis, NA = not applicable